Free Trial
→ Trump compared today's market to 1929 (From USA Capital Gold) (Ad)tc pixel
OTCMKTS:DSNKY

Daiichi Sankyo 1/31/2025 Earnings Results & Report

Daiichi Sankyo logo
$17.68 -0.54 (-2.96%)
As of 11/10/2026 03:58 PM Eastern

Daiichi Sankyo reported earnings on January 31, 2025. The company reported EPS of $0.22.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Report Date
Time
Before Market Opens

Daiichi Sankyo EPS Results

Actual EPS
$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Daiichi Sankyo Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Earnings FAQ

Daiichi Sankyo (OTCMKTS:DSNKY) reported earnings of $0.22 per share for the quarter. The report was announced on Friday, January 31, 2025.

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Daiichi Sankyo on the company's earnings history page.

Daiichi Sankyo Earnings Headlines

IDEL, Daiichi Sankyo Team Up To Test Multi-Drug Conjugate For Solid Tumors
November 9 at 10:03 AM  |  rttnews.comhttps://www.rttnews.com/3711690/idel-daiichi-sankyo-team-up-to-test-multi-drug-conjugate-for-solid-tumors.aspx
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Earnings Beat
November 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31176782
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
November 11 at 1:00 AM  |  Weiss Ratings (Ad)
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript
October 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4960123-daiichi-sankyo-company-limited-dsnky-q2-2026-earnings-call-transcript
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results
October 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261029887292/en/daiichi-sankyo-reports-second-quarter-fiscal-year-2026-financial-results/
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4928580-daiichi-sankyo-company-limited-dsnky-q1-2026-earnings-call-transcript
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions.

Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib). Daiichi Sankyo also invests in research and development, including antibody-drug conjugates and other targeted therapies.

Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets, including the United States and Europe. It works with partners in some markets to develop and commercialize medicines.

View Daiichi Sankyo Profile
Earnings Tools